Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

Ty21a immunotherapy of non-muscle-invasive bladder cancer

Funder: Swiss National Science Foundation

Funding period
CHF 429 K
USD 437 K
Funding amount
Abstract
Ty21a immunotherapy of non-muscle-invasive bladder cancer1. SUMMARY Bladder cancer is the fourth and eighth most common malignancy among men and women, respectively. Seventy percent of tumors present as non muscle-invasive bladder cancer (NMIBC) at initial diagnosis with variable risk of recurrence and progression to invasive disease, thus requiring long-term surveillance. Intravesical BCG immunotherapy can reduce recurrence/progression of NMIBC, although significant adverse events and treatment failure argue for alternative options. During the ongoing granting period we have examined how another live vaccine, Vivotif®, consisting of the highly attenuated Salmonella enterica serovar Typhi strain Ty21a, used since more than 30 years against typhoid fever, may be safely used intravesically to improve bladder-tumor treatment. Our prepreclinical data demonstrate that Ty21a is more efficient than BCG at regressing established bladder tumor in the MB49-orthotopic murine model of NMBIC. This was confirmed by the ability of Ty21a to kill human tumor-cells in vitro and induce, in a novel human 3D-bladder-tissue ex-vivo assay, specific cytokines/chemokines/growth factors associated with efficient bladder-treatment. Our data confirmed a high safety, with no Ty21a bacteria persisting in mouse and human bladder tissues in contrast to BCG. Altogether, these data are of good premise for the use of the typhoid vaccine for intravesical immunotherapy of NMIBC patients.The purpose of this grant proposal is to achieve a two-steps Phase I trial with Ty21a, in order to obtain safety and immunogenicity data in patients, together with hints towards efficacy.
Similar projects All >
Sorted by: Start Date
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2019 - 2020
Project list item
Combatting Bladder Cancer by Inducing Epithelial Turnover

National Cancer Institute to SOMAN N ABRAHAM

USD 203,510
2019 - 2021
Project list item
Phase 1/2 Study of Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder - (ADAPT-BLADDER)

National Cancer Institute to NOAH M HAHN

USD 656,816
2019 - 2024
Project list item
Development of an automated method to capture bladder cancer recurrence and progression for epidemiologic research

National Cancer Institute to KIM N DANFORTH

USD 172,270
2019 - 2021
Project list item
Identifying DNA Biomarkers of Bacillus Calmette-Guerin (BCG) Resistance in Non-Muscle-Invasive Bladder Cancer

Canadian Institutes of Health Research to Jack Victor Warren Bacon, Alexander William Wyatt

USD 847
2018 - 2019

System

Categories
  • FOR (ANZSRC)

    1103 Clinical Sciences

  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Biotechnology

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Immunization

  • RCDC

    Rare Diseases

  • RCDC

    Urologic Diseases

  • RCDC

    Vaccine Related

  • HRCS HC

    Cancer

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science